![]() This drug, Yale-New Haven Hospital Chief of Psychiatry John Krystal told The Daily Beast, “has caused us to question most of our prevailing assumptions about the treatment of depression.” So far, Spravato has been revolutionary for the field of psychiatry as a whole, in part because it seems to act very differently than other available antidepressants. This approval, along with large-scale clinical trials of LSD, MDMA, and psilocybin (the active component of magic mushrooms), marks a sea-change in the medical community’s perception of psychedelics: Instead of viewing them purely as drugs of abuse, many clinicians are now seeking to repurpose them as therapeutics. The drug, called Spravato, is the first psychedelic drug to be approved for the treatment of mental illness. In 2019, the FDA made a groundbreaking decision to approve a form of ketamine as a clinical treatment for patients suffering from treatment-resistant depression, a condition which is estimated to affect nearly three million Americans. ![]() ![]() Photo Illustration by Thomas Levinson/The Daily Beast/Getty
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |